CEF10, Epstein-Barr Virus LMP2 (426-434)

Product Name: CEF10, Epstein-Barr Virus LMP2 (426-434)

Sequence One Letter Code: CLGGLLTMV

Sequence Three Letter Code: H-Cys-Leu-Gly-Gly-Leu-Leu-Thr-Met-Val-OH

Chemical Formula:C39H71N9O11S2

Molecular Weight: 906.2

Purity: 95%

Form: Lyophilized

Storage Conditions: - 20 °C

Research Area: Inflammation and Immunology Research

Source / Species: EBV

Conjugation: Unconjugated

Code Nacres: NA.26

Application: CEF10 is a synthetic peptide corresponding to amino acid residues 426–434 of the Epstein–Barr virus latent membrane protein 2 and represents a well-characterized HLA-A2.1–restricted CD8⁺ T cell epitope. This peptide is widely used to investigate MHC class I–restricted antigen presentation and virus-specific cytotoxic T lymphocyte responses. It enables detailed study of EBV-specific T cell activation, cytokine secretion, and cytolytic function in individuals expressing HLA-A2.1. CEF10 serves as a defined antigenic reagent for immune monitoring, vaccine research, and evaluation of antiviral immune competence. Because Epstein–Barr virus establishes lifelong latent infection, analysis of LMP2-derived epitopes provides insight into immune surveillance mechanisms and T cell–mediated control of viral persistence. The peptide supports both basic and translational research aimed at understanding EBV immunity, immune memory formation, and T cell functionality in infection and immune-related disorders.

Current Research: CEF10 is a synthetic peptide corresponding to amino acid residues 426–434 of Epstein–Barr virus (EBV) latent membrane protein 2 (LMP2) and represents a well-defined HLA-A*02:01–restricted CD8⁺ T cell epitope. As a minimal MHC class I ligand, it is widely used to investigate antigen presentation, T cell receptor (TCR) recognition, and virus-specific cytotoxic T lymphocyte (CTL) responses in HLA-A2.1–positive individuals. EBV establishes lifelong latency in B cells following primary infection. During latency, viral proteins such as LMP2 are expressed to maintain viral persistence while minimizing immune detection. Despite this restricted expression profile, LMP2-derived epitopes are recognized by CD8⁺ T cells and contribute to immune surveillance. CEF10 provides a defined antigenic determinant for dissecting how the immune system detects and controls latent EBV infection. In antigen presentation studies, CEF10 is used to evaluate peptide binding to HLA-A*02:01 molecules and subsequent TCR engagement. Direct peptide pulsing of antigen-presenting cells enables controlled examination of MHC class I loading and CD8⁺ T cell activation independent of upstream antigen processing steps. This allows precise analysis of T cell specificity, functional avidity, and clonal expansion dynamics. Functionally, CEF10 is commonly applied in ex vivo assays using peripheral blood mononuclear cells from HLA-A2.1–expressing donors. Upon stimulation, EBV-specific CD8⁺ T cells can be assessed for cytokine production, including interferon-γ and tumor necrosis factor-α, as well as degranulation markers such as CD107a. Cytolytic activity can be evaluated through target cell killing assays, supporting quantitative measurement of effector function. These assays provide insight into the magnitude and quality of EBV-specific cellular immunity. CEF10 is also widely used in immune monitoring and translational research. Because EBV infection is nearly universal and persists for life, assessment of LMP2-specific CD8⁺ T cell responses serves as an indicator of immune competence and viral control. Monitoring responses to this defined epitope is particularly relevant in immunocompromised populations, including transplant recipients and individuals with immune deficiencies, where EBV reactivation can lead to lymphoproliferative disorders. In vaccine and immunotherapy research, CEF10 supports evaluation of strategies designed to enhance EBV-specific cellular immunity. Peptide-based stimulation assays allow comparison of baseline and post-intervention T cell responses, facilitating assessment of immunogenicity and durability. The defined HLA restriction ensures reproducibility and enables stratification of study cohorts based on MHC genotype. Mechanistic investigations further employ CEF10 to study TCR–peptide–MHC structural interactions and determinants of immunodominance. Analyses of memory CD8⁺ T cell subsets, including central memory and effector memory populations, often utilize this epitope to characterize long-term antiviral immunity and recall responses. Such studies contribute to understanding how immune memory is maintained during chronic viral latency. Overall, CEF10 is a standardized and immunologically relevant EBV epitope that supports detailed investigation of MHC class I–restricted antigen recognition and CD8⁺ T cell function. Its defined sequence and well-characterized restriction profile make it an essential tool for studying antiviral immune surveillance, immune memory formation, and T cell–mediated control of persistent viral infection in both basic and translational research settings.